• OTS
  • December 31, 2018
SHARE
Post Views: 409

Herter EK, Li D, Toma MA, Vij M, Li X, Visscher D, Wang A, Chu T, Sommar P, Blomqvist L, Berglund D, Ståhle M, Wikstrom JD, Xu Landén N.
J Invest Dermatol. 2018 Dec 27. pii: S0022-202X(18)01301-5.

PubMed

Related articles

miR-135a-5p mediates memory and synaptic impairments via the Rock2/Adducin1 signaling pathway in a mouse model of Alzheimer’s disease

miR-135a-5p mediates memory and synaptic impairments via the Rock2/Adducin1 signaling pathway in a mouse model of Alzheimer’s disease

April 23rd, 2021
Small extracellular vesicles containing miR-486-5p promote angiogenesis after myocardial infarction in mice and nonhuman primates

Small extracellular vesicles containing miR-486-5p promote angiogenesis after myocardial infarction in mice and nonhuman primates

April 23rd, 2021
Decreased miR-214-3p activates NF-κB pathway and aggravates osteoarthritis progression

Decreased miR-214-3p activates NF-κB pathway and aggravates osteoarthritis progression

April 23rd, 2021
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

April 23rd, 2021
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

April 23rd, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

April 23rd, 2021